An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound
Phase 4
Withdrawn
- Conditions
- Psoriasis
- Interventions
- Other: PlaceboBiological: Secukinumab 300 mg
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04488185
A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 111
- Registration Number
- NCT04486716
- Locations
- 🇺🇸
Alabama Neurology Associates PC, Birmingham, Alabama, United States
🇺🇸AMO Corporation, Tallahassee, Florida, United States
🇺🇸University Of South Florida, Tampa, Florida, United States
Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT04480853
- Locations
- 🇨🇳
Novartis Investigative Site, Taoyuan, Taiwan
Canakinumab MAP in COVID-19 Pneumonia With CRS
- Conditions
- Cytokine Release Syndrome in COVID-19-induced Pneumonia
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04476706
Managed Access Program to Provide Access to Alpelisib for Patients With Advanced Breast Cancer
- Conditions
- HR+, HER2-, Advanced Breast Cancer
- First Posted Date
- 2020-07-16
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04473040
A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04460729
Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)
Phase 2
Withdrawn
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Interventions
- Biological: Tisagenlecleucel
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04456023
A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC
Phase 2
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT04452877
- Locations
- 🇨🇳
Novartis Investigative Site, Shanghai, China
Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)
Phase 1
Active, not recruiting
- Conditions
- Sickle Cell Disease
- Interventions
- Biological: OTQ923
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT04443907
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Memorial Sloan Kettering Cancer Ctr, New York, New York, United States
🇺🇸St Jude Children's Research Hospital, Memphis, Tennessee, United States
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
Phase 3
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT04427072
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
© Copyright 2025. All Rights Reserved by MedPath